Xuanzhu Biopharma H1 FY26 net loss narrows 32.1% to RMB 75.34 million; revenue more than doubled to RMB 69.44 million

• Xuanzhu Biopharmaceutical revenue rose to RMB 69.4 million, up 288.1% year over year.
• Loss attributable to owners narrowed 32.1% to RMB 75.34 million; basic loss per share improved to RMB 0.15.
• Operating expenses fell 22.2% to RMB 93.4 million, despite selling and distribution costs climbing to RMB 41.55 million.
• Gross profit increased to RMB 15.33 million; gross margin fell to 22.1% from 57% on NRDL pricing for Bireociclib.
• Business update: Bireociclib won a first-line HR+/HER2- approval in March; Anaprazole reflux-esophagitis NDA was accepted in June.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12299523), on August 26, 2026, and is solely responsible for the information contained therein.